The composition of Gerresheimer AG's Supervisory Board has been updated to align with the company's changed shareholder structure, marking a significant shift in corporate governance for the pharmaceutical packaging and medical device manufacturer. Klaus Rohrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board until the next Annual General Meeting in June 2026. He replaces Dr. Dorothea Wenzel, who voluntarily made her position available to ensure the board's composition accurately reflects the company's current ownership landscape.
This board change carries substantial importance for corporate governance practices within publicly traded companies, particularly in the pharmaceutical sector where oversight and regulatory compliance are critical. The appointment demonstrates how shareholder structure changes can directly influence board composition and corporate decision-making processes. Rohrig's background with the Active Ownership Group suggests a focus on shareholder interests and active ownership principles that could shape Gerresheimer's strategic direction.
Beyond the board appointment, Rohrig will also assume Dr. Wenzel's responsibilities on the Audit Committee, a crucial oversight body responsible for financial reporting integrity and internal controls. This dual role places him in a position to influence both strategic governance and financial oversight at a company that generated approximately EUR 2.4 billion in revenue in 2024 and employs around 13,600 people globally. The Audit Committee role is particularly significant given Gerresheimer's position as a MDAX-listed company on the Frankfurt Stock Exchange.
Dr. Axel Herberg, Chairman of the Supervisory Board, acknowledged Dr. Wenzel's contributions, stating she made significant contributions to fulfilling the committee's duties through her expertise and experience. This transition highlights the importance of board continuity while adapting to ownership changes, a balance that publicly traded companies must maintain to ensure stable governance.
The company's upcoming Annual General Meeting on June 3, 2026, will feature Rohrig standing for election to the Supervisory Board, along with three other shareholder representatives. This broader election process for Gerresheimer's co-determined Supervisory Board indicates ongoing evolution in the company's governance structure beyond this immediate appointment.
For the pharmaceutical and healthcare industries that Gerresheimer serves, this governance change could influence how the company addresses growing demands for enhanced sustainability and digital healthcare solutions. As an innovative systems and solutions provider for pharma, biotech, and cosmetic industries, Gerresheimer's leadership decisions impact drug containment, delivery systems, and medical devices used globally. The company's comprehensive portfolio includes digital solutions for therapy support, on-body devices, syringes, pens, auto-injectors, inhalers, and various drug containment products that ensure safe delivery and reliable administration of medications to patients.
With over 40 production sites across 16 countries in Europe, America, and Asia, Gerresheimer maintains a global presence that serves regional markets worldwide. More information about the company's operations and products can be found at https://www.gerresheimer.com. This board change represents how corporate governance adapts to reflect shareholder interests while maintaining oversight of critical healthcare infrastructure that affects patient safety and medication delivery worldwide.
